Arcus Biosciences RCUS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$369M+5.6% | -$353M-24.7% | -$341M-26.3% | -$298M-19.7% | -$391M-69.3% | ||
| $9M-10.0% | $10M0.0% | $10M0.0% | $10M+11.1% | $10M+11.1% | ||
| $63M-12.5% | $60M-21.1% | $62M-19.5% | $67M-11.8% | $72M-2.7% | ||
| $18M+157% | $24M+700% | $29M— | $15M— | $7M— | ||
| -$2M+88.2% | -$5M+77.3% | -$11M+21.4% | -$6M-200% | -$17M— | ||
| —— | —— | —— | —— | $20M— | ||
| —— | —— | $3M— | $2M— | $3M— | ||
| -$229M— | -$240M— | -$256M— | —— | —— | ||
| $7M0.0% | $7M0.0% | $7M0.0% | $6M-25.0% | $7M-12.5% | ||
| -$488M— | -$482M— | -$462M— | —— | —— | ||
| —— | —— | —— | —— | $3M-88.0% | ||
| —— | —— | —— | —— | —— | ||
| $287M— | $429M— | —— | —— | —— | ||
| $349M+81.8% | $488M+74.9% | $202M-28.4% | $242M+0.8% | $192M-26.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | $7M+600% | $5.5M+633% | $4M+700% | $2.5M+900% | ||
| $12M-47.8% | $13M-48.0% | $16M-36.0% | $19M-20.8% | $23M+9.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $20M— | ||
| $7M0.0% | $7M0.0% | $7M0.0% | $6M-25.0% | $7M-12.5% | ||
| $13M+62.5% | $10M+11.1% | $6M-33.3% | $8M0.0% | $8M0.0% | ||
| -$229M— | -$240M— | -$256M— | —— | —— | ||
| -$489M— | -$484M— | -$464M— | —— | —— | ||
| -$489M— | -$484M— | -$464M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arcus Biosciences generate?
- Arcus Biosciences (RCUS) generated -$488.0M in operating cash flow over the trailing twelve months.
- What is Arcus Biosciences's free cash flow?
- After $3.0M of capital expenditures, Arcus Biosciences's free cash flow was -$489.0M over the trailing twelve months, down 46.4% year over year.
- Where does Arcus Biosciences's cash flow data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
